Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Nov 19, 2025 · CIK: 882361
Sentiment: neutral
Topics: financial-reporting, disclosure
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Nov 19, 2025, with financial updates.
AI Summary
Aptose Biosciences Inc. filed an 8-K on November 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This filing indicates routine corporate reporting, including financial updates and disclosures, which are important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and disclosures, not indicating any immediate material changes or risks.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- November 19, 2025 (date) — Date of earliest event reported
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 19, 2025.
What were Aptose Biosciences Inc.'s former names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which country is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the Standard Industrial Classification code for Aptose Biosciences Inc.?
The Standard Industrial Classification code for Aptose Biosciences Inc. is 2836, for Biological Products (no diagnostic substances).
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-11-19 06:02:30
Filing Documents
- f8k_111925.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 21KB
- 0001171843-25-007415.txt ( ) — 234KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_111925_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 19, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: November 19, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer